Get the Stockscreener App
8.10
2.89%
-0.20
Biohaven Ltd stock is traded at $8.10, with a volume of 3.05M.
It is down -2.89% in the last 24 hours and down -49.47% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$8.30
Open:
$8.64
24h Volume:
3.05M
Relative Volume:
0.91
Market Cap:
$1.10B
Revenue:
-
Net Income/Loss:
$-766.97M
P/E Ratio:
-1.0574
EPS:
-7.66
Net Cash Flow:
$-646.43M
1W Performance:
+3.47%
1M Performance:
-49.47%
6M Performance:
-49.69%
1Y Performance:
-81.84%
1-Day Range:
$7.99
$8.785
1-Week Range:
$7.48
$8.785
52-Week Range:
$7.48
$47.75
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
8.09 | 1.10B | 0 | -766.97M | -646.43M | -7.66 |
|
ARGX
Argen X Se Adr
|
926.23 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.00 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
195.69 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
378.76 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.25 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven Ltd. Stock (BHVN) Opinions on Insider Buying and Public Offering - Quiver Quantitative
Morgan Stanley cuts Biohaven stock price target to $26 on FDA setback - Investing.com India
Biohaven Insider Bought Shares Worth $24,999,998, According to a Recent SEC Filing - MarketScreener
Biohaven Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing - MarketScreener
Vlad Coric, Biohaven CEO, buys $5m in BHVN stock By Investing.com - Investing.com Australia
Biohaven Ltd: director Bailey buys $3m in shares By Investing.com - Investing.com Nigeria
Biohaven Ltd: director Childs buys $25m in common shares - Investing.com
Biohaven Ltd: director Bailey buys $3m in shares - Investing.com
Building trade automation scripts for Biohaven Ltd.July 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
2025 Power 25 Health Care: Vlad Coric - Hartford Business Journal
Can Biohaven Ltd. stock resist sector downturnsRate Cut & Real-Time Volume Analysis - newser.com
William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth - Finviz
Why hedge funds are buying Biohaven Ltd. stockJuly 2025 Breakouts & Weekly High Return Opportunities - newser.com
What drives Biohaven Ltd stock priceEconomic Indicators Overview & Free Long-Term Investment Planning - earlytimes.in
Why retail investors pile into Biohaven Ltd. stockQuarterly Portfolio Report & Daily Volume Surge Signals - newser.com
Is Biohaven Ltd. stock a buy for dividend growthJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - newser.com
Will Biohaven Ltd. stock reach Wall Street targetsQuarterly Portfolio Report & High Accuracy Buy Signal Tips - newser.com
What Fibonacci levels say about Biohaven Ltd. reboundJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
Signal strength of Biohaven Ltd. stock in tech scannersJuly 2025 Analyst Calls & Community Verified Swing Trade Signals - newser.com
Why Biohaven Ltd. stock is favored by pension fundsDip Buying & Fast Gain Stock Tips - newser.com
Earnings visualization tools for Biohaven Ltd.Quarterly Trade Summary & Consistent Profit Trading Strategies - newser.com
A Look at Biohaven’s Valuation Following $175 Million Share Offering and Recent FDA Setback - simplywall.st
The Technical Signals Behind (BHVN) That Institutions Follow - news.stocktradersdaily.com
Market reaction to Biohaven Ltd.’s recent newsEarnings Risk Summary & Technical Buy Zone Confirmation - newser.com
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M - Your Wyoming Link
Why Biohaven (BHVN) Is Down 5.3% After $175M Equity Raise and Pipeline Reprioritization - simplywall.st
Has Biohaven Ltd. formed a bullish divergenceJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Will Biohaven Ltd. stock gain from government policiesWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Is Biohaven Ltd. stock vulnerable to regulatory risksPortfolio Return Report & Stock Portfolio Risk Management - newser.com
Will Biohaven Ltd. stock maintain momentum in 2025Weekly Trend Summary & Advanced Swing Trade Entry Alerts - newser.com
How Biohaven Ltd. stock benefits from global expansionWeekly Trade Report & Verified Technical Trade Signals - newser.com
How Biohaven Ltd. Common Shares stock trades in high volatilityM&A Rumor & Growth Oriented Trade Recommendations - newser.com
Biohaven closes upsized public offering, raises $200 million By Investing.com - Investing.com Nigeria
Biohaven Ltd. Raises $200M in Public Offering - TipRanks
Biohaven (BHVN): Citigroup Lowers Price Target, Maintains Buy Ra - GuruFocus
Ropes & Gray Advised Underwriters in $175 Million Public Offering for Biohaven Ltd. - Ropes & Gray
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.58%
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):